



When getting back  
to the clinic becomes  
a little difficult

Warticon is a highly effective treatment  
for male genital warts situated in the  
preputial space.<sup>1,2,3</sup>

It can be applied by the patient, in his  
own home, twice daily for three days,  
following an initial visit to a GUM clinic.


Warticon therefore relieves the patient,  
and the clinic, of the time and effort of  
regular attendance for treatment.<sup>1</sup>

**Warticon**  
podophyllotoxin 0.5% w/v

Simple enough for self-application in  
male genital warts

 **Perstorp Pharma**

Further information is available from: Perstorp Pharma Ltd, Intec 2, Wade Road, Basingstoke,  
Hants RG24 0NE Tel: (0256) 477868

 and Warticon are registered trademarks

#### ABBREVIATED PRESCRIBING INFORMATION

**Warticon:** Podophyllotoxin 0.5% w/v. **Presentation:** An acidic ethanolic solution of 0.5% w/v podophyllotoxin. **Uses:** For the treatment of penile warts (condylomata acuminata), located in the preputial space. **Dosage and Administration:** The affected area should be washed and dried prior to application. Using the applicator provided, the warts should be painted twice daily for 3 days. The treated area should be allowed to dry. Treatment may be repeated after 7 days. Maximum single dose of 30 loops per application for at-home treatment (50 loops under medical supervision). Where lesions are greater in area than 4cm<sup>2</sup>, it is recommended that treatment takes place under the direct supervision of medical staff. **Contraindications, Warnings, etc:** Open wounds, hypersensitivity to podophyllotoxin. In the event of the preparation entering the eye, the eye should be thoroughly bathed in water. **Side effects:** Local irritation may occur. In the majority of cases the reactions are mild. **Overdosage:** No overdoses have been reported. No specific antidote is known. Following accidental spillage, wash the affected area with soap and water. In the event of accidental ingestion give emetic or stomach washout. Treatment should be symptomatic. **Pharmaceutical Precautions:** Store at room temperature. **Package Quantities:** Bottle containing Warticon 3ml. Plastic applicators are also enclosed in each pack. Each loop will carry 5µl Warticon Solution. **Legal Category:** POM. Basic NHS Cost: 3 ml £16.00. **Product Licence Number:** PL 3863/0007.

#### REFERENCES

1. Pickering RW. Br J Sex Med 1989; 16: 320-324.
2. Lassus A, *et al.* Eur J Sex Trans Dis 1984; 2: 31-33.
3. von Krogh G. In Derm in Five Continents. Proceedings of the XVII World Congress of Dermatology 1987: 317-326.

# BMJ Publishing Group

# Journals

**BMJ**

*Published Weekly*

Annals of the Rheumatic Diseases - *monthly*  
Archives of Disease in Childhood - *monthly*  
British Heart Journal - *monthly*  
British Journal of Industrial Medicine - *monthly*  
British Journal of Ophthalmology - *monthly*  
Cardiovascular Research - *monthly*  
Genitourinary Medicine - *bi-monthly*  
Gut - *monthly*  
Journal of Clinical Pathology - *monthly*  
Journal of Epidemiology and Community Health - *bi-monthly*  
Journal of Medical Ethics - *quarterly*  
Journal of Medical Genetics - *monthly*  
Journal of Neurology, Neurosurgery and Psychiatry - *monthly*  
Quality in Health Care - *quarterly*  
Thorax - *monthly*  
Tobacco Control: An International Journal - *quarterly*

---

BMA News Review - *monthly*  
British Dental Journal - *22 issues a year*  
BDA News - *19 issues a year*  
British Journal of Anaesthesia - *monthly*  
Bulletin of Medical Ethics - *10 issues a year*  
Current Work in the History of Medicine - *quarterly*  
Eye - *bi-monthly*  
Health Visitor - *monthly*  
Medical History - *quarterly*  
Medical History Supplement - *annually*


*For full details or a sample copy please contact:  
Rachel Armitage, Journals Marketing, BMJ Publishing Group,  
BMA House, Tavistock Square, London WC1H 9JR*

# Rights and Responsibilities of Doctors

SECOND EDITION (1992)

Doctors have rights and responsibilities and duties and powers which require them to do or not to do certain things in certain circumstances. Doctors' actions, as well as being governed by their professional code, are also regulated by a variety of legislation with which they must comply. Examples include the various Public Health Acts, the Misuse of Drugs Act, the Human Fertilisation and Embryology Act, the Data Protection Act, the Access to Health Records Act, and so on. As well as United Kingdom legislation, doctors are increasingly being affected by laws emanating from the European Community.

*Rights and Responsibilities* provides a practical guide to the law as it affects doctors. It aims to cover the main areas that are of interest and concern to most doctors. Designed as a handbook, the style affords easy access to individual topics and offers succinct but



comprehensive advice. As well as doctors, medical students, health service administrators, lawyers with an interest in medical law, local authority officers, and others with an interest in the legal aspects of medicine will find this book invaluable.

ISBN 0 7279 0753 0 226 pages

Price: Inland £10.95

Abroad £13.00

BMA members: Inland £9.95

Abroad £12.00


# The Unacceptable Face of Science

Fraud exists, both in academic medical research and in drug trials in general practice. This important new book sets out the evidence, reviewing events since 1975 when the first notorious case of fraud became public knowledge.

The problem is viewed from many perspectives, with contributions from a general practitioner, head of an academic unit, contract research company director, statistician, editor and lawyer. Together, their information provides a compelling account of the extent to which fraud and misconduct have been and continue to be practised in medicine.

## Contents include:

- fraud in general practice
- statistical aspects of detection
- the British Pharmaceutical Industry's response
- legal aspects
- the French scene
- the Danish scene
- data audits in trials and their implications for misconduct
- fraud and the editor



*Fraud and Misconduct in Medical Research* is a valuable practical text for all researchers – and ultimately anyone who practises medicine.

ISBN: 0 7279 0757 3

Publication date: January 1993

Price: UK £24.95;

Overseas £27.00

(including postage by air abroad)

BMA Members Price: UK £22.95;

Overseas £25.00

(including postage by air abroad)

Available from: British Medical Journal, PO Box 295, London WC1H 9LP; medical booksellers or the BMJ Bookshop in BMA House (*book tokens accepted, UK only*)

☐ Please send me \_\_\_\_\_ copy(ies) of

## ▼ RIGHTS AND RESPONSIBILITIES OF DOCTORS

Enclose ☐ £ \_\_\_\_\_ BMA Membership No. \_\_\_\_\_

☐ Please make cheques payable to **British Medical Journal**

Debit my credit card (*please tick box*)

VISA

AMERICAN EXPRESS

MASTERCARD

Card No. \_\_\_\_\_

Card expiry date: \_\_\_\_/\_\_\_\_/\_\_\_\_

Signature \_\_\_\_\_

Name \_\_\_\_\_

Address \_\_\_\_\_

Postcode \_\_\_\_\_

☐ Please send me a BMJ book catalogue.

Available from: British Medical Journal, PO Box 295, London WC1H 9LP; medical booksellers or the BMJ Bookshop in BMA House (*book tokens accepted, UK only*)

☐ Please send me \_\_\_\_\_ copy(ies) of

## ▼ Fraud and Misconduct in Medical Research

Enclose ☐ £ \_\_\_\_\_ BMA Membership No. \_\_\_\_\_

☐ Please make cheques payable to **British Medical Journal**

Debit my credit card (*please tick box*)

VISA

AMERICAN EXPRESS

MASTERCARD

Card No. \_\_\_\_\_

Card expiry date: \_\_\_\_/\_\_\_\_/\_\_\_\_

Signature \_\_\_\_\_


Name \_\_\_\_\_

Address \_\_\_\_\_

Postcode \_\_\_\_\_

☐ Please send me a BMJ book catalogue.

**Abbreviated prescribing information** *Indications and dosage:* Systemic candidiasis: 400mg on the first day followed by 200-400mg once daily. Cryptococcosis, including meningitis: 400mg on the first day followed by 200-400mg once daily. Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with AIDS: 100-200mg daily. Oropharyngeal candidiasis: 50-100mg once daily for 7-14 days or longer in immunocompromised patients. Other mucosal candidal infections: 50-100mg once daily for 14-30 days. Prevention of fungal infections in neutropenic patients following cytotoxic chemotherapy or radiotherapy: 50-100mg once daily whilst patients are predisposed to such infections. Dermal fungal infections: 50mg once daily for up to 6 weeks (usually 2-4 weeks - see data sheet). Vaginal candidiasis: single 150mg dose. Use in the elderly - as above except for those renally impaired - see data sheet. Use in children - not recommended. *Administration:* DIFLUCAN may be administered either orally or by intravenous infusion at a rate of approximately 5-10ml/min. The dosages for the two routes are equivalent. *Contra-indications:* Hypersensitivity to fluconazole or related azoles, pregnancy and women of childbearing potential unless adequate contraception is employed. *Warnings:* Lactation: Not recommended. Renal impairment: dosage reduction may be necessary, see data sheet. *Drug interactions:* Anticoagulants, cyclosporin, oral sulphonylureas, phenytoin, rifampicin or theophylline. *Side-effects:* Nausea, abdominal discomfort, diarrhoea, flatulence and rarely anaphylaxis. *Legal Category:* POM. *Package Quantities and Basic NHS Cost:* 50mg capsule, calendar pack of 7, £16.61 (PL 57/0289); 200mg capsule, calendar pack of 7, £66.42 (PL 57/0317); 150mg capsule, pack of 1, £7.12 (PL 57/0290); Powder for Oral Suspension, 35ml after reconstitution with water: Bottle of 50mg/5ml, £16.61 (PL 57/0343), Bottle of 200mg/5ml, £66.42 (PL 57/0344); Bottles of 25ml and 100ml containing DIFLUCAN 2mg/ml intravenous infusion - 25ml (50mg) bottle, £7.32; 100ml (200mg) bottle, £29.28 (PL 57/0315). Hospital prices are available on request. Date of preparation Dec 92. *References:* 1. Data on file, Pfizer Ltd. 2. Brammer, K.W. (1990), *Haematology and Blood Transfusion*, 33, 546-550. 3. Samonis, G. et al. (1990), *Reviews of Infectious Diseases*, 12(3), S369-S373. 4. Data on file, Pfizer Ltd. 5. Buxton, M.J. et al. (1991), *Journal of Infection*, 23, 17-31. Further information on request. \*Trade Mark. Pfizer Limited, Sandwich, Kent.



DIFLUCAN\* is a highly effective antifungal agent with activity against a wide range of common invasive fungal infections.<sup>1</sup> It should be considered as a first-line treatment in suspected or proven candidal or cryptococcal infections. DIFLUCAN also provides effective prophylactic therapy in neutropenic patients and in patients with solid tumours.<sup>2,3</sup>

DIFLUCAN has a good safety profile and is well tolerated in both its oral and intravenous forms.<sup>4</sup> Since DIFLUCAN is generally better tolerated than I.V. amphotericin B, patients require less hospital care and can be treated on an outpatient basis thus facilitating a substantial reduction in costs.<sup>5</sup>

**Diflucan**\* ORAL/I.V. Counters invasive fungal infection.  
fluconazole \*Trade Mark